This suggests that fisetin can suppress ACD-related disease pathology by enhancing anti-inflammatory IL-10 and TGF-β production while downregulating levels of inflammatory mediators including IL-17A, IL-6, and TNF-α. This evidence concerns the gene TGFB1 and granular corneal dystrophy type II.